Optinose Inc   (OPTN)
Other Ticker:  
Price: $1.6900 $0.04 2.424%
Day's High: $1.75 Week Perf: 26.12 %
Day's Low: $ 1.60 30 Day Perf: 17.36 %
Volume (M): 555 52 Wk High: $ 2.07
Volume (M$): $ 938 52 Wk Avg: $1.38
Open: $1.69 52 Wk Low: $0.90

 Market Capitalization (Millions $) 190
 Shares Outstanding (Millions) 112
 Employees -
 Revenues (TTM) (Millions $) 72
 Net Income (TTM) (Millions $) -41
 Cash Flow (TTM) (Millions $) 6
 Capital Exp. (TTM) (Millions $) 0

Optinose Inc
Optinose Inc is a pharmaceutical company that specializes in developing and commercializing innovative treatments for patients with various medical conditions. The company focuses on utilizing its proprietary Optinose Exhalation Delivery System (EDS) technology, which delivers drugs through the nose, to maximize drug delivery and improve patient outcomes.

Optinose's EDS technology enables targeted drug delivery to specific areas of the nasal cavity and sinuses, potentially providing more effective treatment options for conditions such as chronic rhinosinusitis, nasal polyps, and migraines. By delivering drugs directly to the site of action, the company aims to minimize systemic side effects and enhance therapeutic benefits.

Through its research and development efforts, Optinose has developed a pipeline of potential treatments, including its flagship product, XHANCE, for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE has been approved by the United States Food and Drug Administration (FDA) and is commercially available in the United States.

Overall, Optinose Inc strives to leverage its innovative EDS technology to improve patient's lives by providing targeted and effective treatments for various medical conditions affecting the nasal cavity and sinuses.

   Company Address: 1020 Stony Hill Road Yardley 19067 PA
   Company Phone Number: 364-3500   Stock Exchange / Ticker: NASDAQ OPTN
   OPTN is expected to report next financial results on March 06, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Product Service News

Innovative Nasal Spray XHANCE Proven Effective in Treating Chronic Sinusitis, According to Optinose's ReOpen Clinical Trials

Published Thu, Jan 18 2024 5:00 PM UTC

Optinose Announces Positive Results of XHANCE Clinical Trial in the Journal of Allergy and Clinical Immunology: In Practice Optinose, a pharmaceutical company specializing in innovative therapies for chronic sinusitis, has recently published the findings of the ReOpen Phase 3 Clinical Trial Program in the prestigious Journal of Allergy and Clinical Immunology: In Practice. T...

Optinose Inc

Optinose Inc Achieves Revenue Consolidation Amid Positive Stock Market Trends from July to September 30, 2023

Optinose Inc, a pharmaceutical company specializing in major preparations, has experienced a recent increase in its share prices. Over the past month, its shares went up by 7.89%, while in the past week, they saw a 4.24% increase. These positive stock market trends indicate a promising outlook for the company.
It is important to note that Optinose Inc's shares are currently trading 36.7% higher than its 52-week low, further reinforcing the company's upward momentum. Investors and analysts are likely taking notice of this positive growth trajectory.

Optinose Inc

Optinose Inc Achieves Impressive Turnaround with Significant Increase in Earnings Per Share

As an avid investor and analyst in the pharmaceutical industry, I couldn't help but take notice of Optinose Inc's recent financial results. The company's performance for the fiscal period ending on June 30, 2023, has left me impressed and optimistic about its future prospects.
First, let's delve into the positive earnings per share (EPS) figures. Optinose Inc managed to generate an EPS of $0.02 per share, a significant turnaround from a loss of $0.23 per share reported a year ago. Furthermore, this marks an improvement from a loss of $0.17 per share in the preceding reporting season. This successful transformation speaks volumes about the company's ability to optimize its operations and increase profitability.

Optinose Inc

Optinose Inc Reports Improved Bottom Line and Stable Finances, Despite Sales Shortfall

Optinose Inc has recently released their financial results for the fiscal interval ending March 31 2023, and despite reporting a loss of $0.17 per share, this is a significant improvement from the $0.31 loss reported a year prior, showcasing a positive trend. Moreover, it is important to take into consideration that the reported loss has been increased by only $0.05 per share from the prior reporting period, which shows that Optinose Inc has managed to stabilize their financial situation.
Even though the company experienced a decline in revenue of -19.743% to $11.85 million from $14.76 million in the corresponding reporting period a year ago, it's important to highlight the sequential Revenue Tumble of -43.201% that impacted the results, resulting in an adverse impact on quarterly revenues. However, these figures should not be seen as an alarming sign for investors, considering the Q1 period has traditionally been a slow quarter due to seasonality and a decrease in doctor visits.


Optinose Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com